Infectious Diseases Pharmacist @BrighamWomens, proud @bethisraellahey and @Northeastern alum #BCIDP #FIDSA #IDTwitter #IDSky, views my ownhttps://bsky.app/profile/jeffpears0n.bsky.socialhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3m6wqnrld6c2gThe Brigham and Women's PGY2 Infectious Diseases Pharmacy Residency is recruiting for the 2026-27 year! Scan the second QR code below to schedule an on-demand meeting with program leadership and current residents01 Dec 2025 15:30 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3m6wqnrld6c2ghttps://bsky.app/profile/jeffpears0n.bsky.social/post/3llegiwiiak27Three new UTI antibiotics active vs. ESBL organisms have been approved by the FDA in the past year alone! Which will make it to market first: pivmecillinam, sulopenem-probenecid, or gepotidacin? #IDsky27 Mar 2025 13:41 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3llegiwiiak27https://bsky.app/profile/jeffpears0n.bsky.social/post/3lhtbtlbivc25The aztreonam-avibactam (Emblaveo) FDA approval Friday flew wayyyy under the radar without the normal FDA alerts or AMDAC review. But AbbVie has the press release (https://news.abbvie.com/2025-02-07-U-S-FDA-Approves-EMBLAVEO-TM-aztreonam-and-avibactam-for-the-Treatment-of-Adults-With-Complicated-Intra-Abdominal-Infections-With-Limited-or-No-Treatment-Options) and the FDA package insert is now available! https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217906Orig1s000lbl.pdf10 Feb 2025 13:47 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lhtbtlbivc25https://bsky.app/profile/jeffpears0n.bsky.social/post/3ldjooxyngs2oGreat to see the CACTUS study in print! https://authors.elsevier.com/c/1kHGc5E-UogXfG Ceftaz-avi vs. Ceftol-tazo for MDR Pseudomonas. Tremendous effort by all involved, and thanks to a great leadership team. The PRECEDENT network is cooking up much more, check it out at www.precedentnetwork.com! #IDsky17 Dec 2024 20:30 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3ldjooxyngs2ohttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbdsf7wvx22oI'm excited to join the #IDSky 🦋 community! What better way to start than with our study that flew under the radar last month integrating vancomycin AUC monitoring in OPAT, which saw HUGE drops in AKI rates (23% to 6% overall). Safe to say AUC is here to stay! https://academic.oup.com/ofid/article/11/11/ofae600/782593120 Nov 2024 01:29 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbdsf7wvx22ohttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhp2pfjst2jThank you @IDSAInfo for this honor! I'm humbled to become a fellow of IDSA, especially being just 1 of 8 PharmDs recognized with #FIDSA this year. I can't wait to see everyone in LA in October at @IDWeekmtg! #WeAreID10 May 2024 21:19 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhp2pfjst2jhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhp2llf2l24Concomitant carbapenem & valproate use is THE most relevant drug interaction I teach residents & students about. In our review, seizures occured in 46% of encounters😱. Avoid this combination at all costs in patients using valproate for seizure control!10 Mar 2024 22:12 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhp2llf2l24https://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhp2hrikf2rAlright #IDTwitter, what would you recommend in the situation below? Source control unattainable, infected graft so hoping for short-term acute treatment and long-term suppression. NDM positive Providencia rettgeri12 Feb 2024 19:43 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhp2hrikf2rhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhp2e4dt22oOur new study evaluating gentamicin dosing strategies for endocarditis was published in @jac_amr! We saw HUGE rates of nephrotoxicity (~50%) in the divided dosing group. Next research question from our MGB group - time to ditch gent altogether?28 Dec 2023 18:47 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhp2e4dt22ohttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhp2a5ctc22Catching up on podcasts today, I had the best random back-to-back listening experience! Looking at the pip-tazo breakpoints from two different angles, great discussion in both from @SIDPharm and @ASMicrobiology & #IDTwitter14 Apr 2023 17:49 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhp2a5ctc22https://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhp24d7tv2rThe tixagevimab-cilgavimab (Evusheld) EUA was revoked today by the FDA, marking the end of these #COVID Mab posts from me for the foreseeable future. #IDtwitter26 Jan 2023 18:47 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhp24d7tv2rhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhozyj42b2bASPE/HHS published a breakdown of oral #COVID19 treatment utilization by state last week - Paxlovid vs. molnupiravir. As I expected, Massachusetts is on the far end of the spectrum favoring Paxlovid... #IDTwitter 1/212 Jan 2023 22:53 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhozyj42b2bhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhozup3dr2yThe @US_FDA officially withdrew bebtelovimab's EUA this week as variant resistance has surpassed 65%, following in the steps of many #COVID Mabs before it. The only Mab left standing (barely) is Evusheld (79% resistant, but no alternatives) #IDTwitter02 Dec 2022 23:18 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhozup3dr2yhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhozr2leo2nI also have joined med Mastodon and will likely be moving over to that platform gradually in the coming weeks, come along for the ride! #medmastodon #IDmastodon #IDTwitter16 Nov 2022 20:13 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhozr2leo2nhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhozn3izu2lI missed last Friday's Tweet, so I added some extra insight in this post. Updated Mab variant table, with expected susceptibility against circulating variants in the second image (per ). We shut down bebtelovimab last week at BWH #IDTwitter #COVID1916 Nov 2022 19:55 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhozn3izu2lhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhozjapdu2lWhile not much has changed on my Mab table since the last post, a whole lot has changed with the current #COVID variants. We're now looking at ~27% resistance to bebtelovimab and ~50% resistance to Evusheld. Stay tuned for updates from @NIHCOVIDTxGuide04 Nov 2022 15:25 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhozjapdu2lhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhozfgnvm2iThis may need to be a weekly Tweet based on how quickly the #COVID19 Omicron variants are changing. Below is the updated COVID Mabs table, and just as importantly the variant situation right now in the US. Note the variants quickly rising to the top of the list... #IDTwitter14 Oct 2022 18:21 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhozfgnvm2ihttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhozaoayf2sOmicron continues its never-ending variant kick! BA.4.6 & BA.2.75 are added below. This will be my last variant table that is all-inconclusive. In order to make more readable going forward it will just be with active(ish) variants and #COVID Mabs #IDTwitter05 Oct 2022 21:51 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhozaoayf2shttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoz4zfou2iOur @BrighamPharmacy team has been on a vancomycin publication kick recently! Out today in @OFIDJournal, we report on our vanc accumulation rates in patients with obesity. Hint: it happens A LOT. Where's the #saynotovanco crowd at?! @PharmerMeg 😂21 Sep 2022 19:19 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoz4zfou2ihttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoyz2cv32tJust in time for the holiday weekend, the FDA authorized re-dosing of Evusheld every 6 months! They also snuck in neutralizing data for BA.4/5, so time for another table update! AstraZeneca says 33-65-fold reduction is OK, what say you? #COVID #IDTwitter30 Jun 2022 13:51 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoyz2cv32thttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoyvkzpm2bThe bebtelovimab fact sheet was updated last week with info on BA.2.12.1, BA.4, and BA.5 (), which means it's time for an update to the #COVID variant table! #IDTwitter23 Jun 2022 23:35 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoyvkzpm2bhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoyrfqpl2tThis flew under the radar (even for me as an author!), but the @BrighamWomens team recently had an excellent (succinct) sepsis review paper published - we discuss time to abx in sepsis v. septic shock, prolonged vs. push 1st dose, order of admin, and more!27 May 2022 17:24 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoyrfqpl2thttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoynlozu2lOh how far we've come! I remember presenting a clinical pearl on Shingrix use in the immunocompromised in early 2018 with no published efficacy data, and now we have plenty! @AnnMarieI3 #MASHP2219 May 2022 14:12 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoynlozu2lhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoyjwtkq2lThis was an absolutely outstanding keynote at #MASHP22, thank you @OjikutuBisola!19 May 2022 13:54 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoyjwtkq2lhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoyfxshs22Out with the old, in with the new! The 2022 ACIP pneumococcal vaccination updates should simplify administration quite a bit. Thanks @AnnMarieI3 for the vaccine update and visuals at #MASHP22!19 May 2022 13:49 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoyfxshs22https://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoycdbnu2iQuestion for #IDTwitter, which would you rather? Uncontrolled intra-abdominal source with MDR Citrobacter freundii and PsA aeruginosa. Are you worried less about ceftaz-avi at breakpoint for PsA or ceftol-tazo and inducible ampC with citrobacter? Poll in next Tweet! @BWDionne18 Apr 2022 17:37 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoycdbnu2ihttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoy6doje2lAnother #COVID Mab Update! Rec for Evusheld now double the dose (already causing local logistical nightmares) based on Omicron activity (see table below) and safety from failed TACKLE treatment study, but no clinical efficacy data25 Feb 2022 15:35 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoy6doje2lhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoy2jwpa2yYou knew it would come on a Friday night! Bebtolivimab received EUA (based on only limited Phase 2 data but promising variant data). Time for a variant table update - more to come on BA1.1 and BA.2 #COVID1912 Feb 2022 15:47 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoy2jwpa2yhttps://bsky.app/profile/jeffpears0n.bsky.social/post/3lbhoxwubdg2oShow me your inpatient COVID waves without showing me your inpatient COVID waves...#IDTwitter #COVID19 #remdesivir21 Jan 2022 14:04 +0000at://did:plc:ggsex2soseqewouekoygihub/app.bsky.feed.post/3lbhoxwubdg2o